Windtree Therapeutics Files 8-K
Ticker: WINTW · Form: 8-K · Filed: Dec 4, 2024 · CIK: 946486
| Field | Detail |
|---|---|
| Company | Windtree Therapeutics Inc /De/ (WINTW) |
| Form Type | 8-K |
| Filed Date | Dec 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, financials, exhibits
TL;DR
Windtree Therapeutics filed an 8-K with financial exhibits, no major news.
AI Summary
On December 4, 2024, Windtree Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant business updates detailed in the provided text.
Why It Matters
This filing indicates Windtree Therapeutics is providing required financial and exhibit information to the SEC, which is standard for public companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any immediate operational or financial distress.
Key Numbers
- 001-39290 — SEC File Number (Identifies the company's filing with the SEC)
- 94-3171943 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Windtree Therapeutics, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976 (address) — Principal executive office address
- Discovery Laboratories Inc /DE/ (company) — Former company name
- Ansan Pharmaceuticals Inc (company) — Former company name
- Ansan Inc (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits as of December 4, 2024.
When was this 8-K report filed?
This 8-K report was filed on December 4, 2024.
What is Windtree Therapeutics, Inc.'s state of incorporation?
Windtree Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Windtree Therapeutics, Inc.?
The principal executive office address is 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976.
Has Windtree Therapeutics, Inc. had previous company names?
Yes, Windtree Therapeutics, Inc. was formerly known as Discovery Laboratories Inc /DE/, Ansan Pharmaceuticals Inc, and Ansan Inc.
Filing Stats: 465 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-12-04 08:02:58
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share WINT The Nasdaq Capital Ma
Filing Documents
- wint20241202_8k.htm (8-K) — 26KB
- ex_753959.htm (EX-99.1) — 15KB
- 0001437749-24-036647.txt ( ) — 179KB
- wint-20241204.xsd (EX-101.SCH) — 3KB
- wint-20241204_def.xml (EX-101.DEF) — 12KB
- wint-20241204_lab.xml (EX-101.LAB) — 15KB
- wint-20241204_pre.xml (EX-101.PRE) — 12KB
- wint20241202_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events On December 4, 2024, Windtree Therapeutics, Inc. (the "Company") issued a press release announcing that the Company has engaged a strategic advisor to lead a process in respect of its cardiovascular portfolio. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Document 99.1 Press Release of Windtree Therapeutics, Inc., dated December 4, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Windtree Therapeutics, Inc. By: /s/ Jed Latkin Name: Jed Latkin Title: President and Chief Executive Officer Date: December 4, 2024